Centene Offloads Two Pharmacy Businesses For $2.8B
Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners. Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…
Benzinga ·